Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 1:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 178 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pneumococcal Vaccines Clear all
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Impact of HIV-1 and Aging on Mucosal Vaccine Responses

NCT03729778
View directory record Official record
Conditions
HIV-1-infection, Human Immunodeficiency Virus, HIV/AIDS, HIV Infections
Interventions
Prevnar-13
Biological
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
21 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 7, 2026, 1:08 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)

NCT04168190
View directory record Official record
Conditions
Pneumonia, Pneumococcal
Interventions
V116, Pneumovax™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
20
States / cities
Birmingham, Alabama • Mesa, Arizona • Coral Gables, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Sep 7, 2026, 1:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine

NCT00589394
View directory record Official record
Conditions
Healthy
Interventions
pneumococcal vaccination (Pneumovax)
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Sep 7, 2026, 1:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

NCT03547167
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™, PNEUMOVAX™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,515 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
38
States / cities
Chinle, Arizona • Fort Defiance, Arizona • Glendale, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Sep 7, 2026, 1:08 AM EDT
Completed No phase listed Observational Results available

Impact of Prevnar 13 on Ear Infections in Children

NCT01272999
View directory record Official record
Conditions
Acute Otitis Media, Mastoiditis
Interventions
No intervention
Other
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Sep 7, 2026, 1:08 AM EDT
Completed Phase 1 Interventional

A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

NCT00000829
View directory record Official record
Conditions
HIV Infections, Pneumococcal Infections
Interventions
Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 6 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
31
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 7, 2026, 1:08 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of wSp Vaccine in Young Children

NCT07216430
View directory record Official record
Conditions
Acute Otitis Media (AOM)
Interventions
wSp vaccine, Saline (0.9% NaCl)
Biological
Lead sponsor
Serum Life Science Europe GmbH
Industry
Eligibility
5 Months to 7 Months
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
7
States / cities
Pittsford, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 7, 2026, 1:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders

NCT00153543
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
PCV7 + PPV23, 2 months, PCV7 + PPV23, 6 months
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
55 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 7, 2026, 1:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age

NCT03313050
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Tdap, polysaccharide
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
511 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
18
States / cities
Birmingham, Alabama • Cerritos, California • Savannah, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 7, 2026, 1:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pneumococcal Conjugate Vaccine With Pneumococcal Polysaccharide Vaccine and Tetanus/Diphtheria Vaccine

NCT00164411
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Tetanus-diphtheria toxoids (Td), 7-valent pneumococcal conjugate vaccine, 23-valent polysaccharide vaccine
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
50 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Sep 7, 2026, 1:08 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants

NCT06524414
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
PG4, 20-valent pneumococcal conjugate vaccine (20vPnC), 15-valent pneumococcal conjugate vaccine (PCV15)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
605 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
61
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • La Puente, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 7, 2026, 1:08 AM EDT
Completed Phase 2 Interventional Results available

Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00445484
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
pneumococcal polyvalent vaccine, lenalidomide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2015 · Synced Sep 7, 2026, 1:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

NCT03692871
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
42 Days to 90 Days
Enrollment
2,409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
22
States / cities
Downey, California • Huntington Beach, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 7, 2026, 1:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

NCT00384397
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
249 Days to 305 Days
Enrollment
1,128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
39
States / cities
Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 7, 2026, 1:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

NCT04526574
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
Experimental 20-valent pneumococcal conjugate vaccine (20vPnC), Saline, Influenza vaccine
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
1,796 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
63
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Sep 7, 2026, 1:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects

NCT00500266
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
13-valent Pneumococcal Conjugate Vaccine (13vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
68 Years and older
Enrollment
1,053 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
40
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Sep 7, 2026, 1:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

NCT03313037
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Prevnar 13, PPSV23, Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years to 64 Years
Enrollment
444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
14
States / cities
Anaheim, California • Coral Gables, Florida • DeLand, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Sep 7, 2026, 1:08 AM EDT
Recruiting Phase 1Phase 2 Interventional

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

NCT03942328
View directory record Official record
Conditions
Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Atezolizumab, Bevacizumab, External Beam Radiation Therapy, Pheresis, Pneumococcal 13-valent Conjugate Vaccine, Therapeutic Autologous Dendritic Cells, Durvalumab, Esophagogastroduodenoscopy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Biopsy Procedure, Biospecimen Collection
Biological · Radiation · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 7, 2026, 1:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.

NCT04583618
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb, Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI, Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII, Pneumococcal 13 - valent conjugate vaccine-Prevnar 13, Pneumococcal Vaccine Polyvalent-Pneumovax 23
Biological
Lead sponsor
Sanofi
Industry
Eligibility
50 Years to 84 Years
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
17
States / cities
Anaheim, California • Rolling Hills Estates, California • Wheat Ridge, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 7, 2026, 1:08 AM EDT
Completed No phase listed Observational

Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired Pneumonia

NCT01086397
View directory record Official record
Conditions
Pneumonia, Pneumococcal, Vaccines, Pneumococcal
Interventions
Urine sample collection
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Mobile, Alabama • La Mesa, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Sep 7, 2026, 1:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)

NCT03480763
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™, PNEUMOVAX™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
652 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
15
States / cities
Chandler, Arizona • Phoenix, Arizona • Spring Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 7, 2026, 1:08 AM EDT
Completed No phase listed Observational Results available

Vaccine Immune Recovery After Leukemia

NCT05622682
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Pediatric
Interventions
Observational only: Serology and flow cytometry for ALL cohort participants, Observational only: Infection rates
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
3 Years to 31 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Chicago, Illinois • Grand Rapids, Michigan • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 7, 2026, 1:08 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation

NCT06181656
View directory record Official record
Conditions
Pneumococcal Vaccine, Esophageal Cancer, Lymphopenia, Chemoradiation
Interventions
Pneumonia vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 7, 2026, 1:08 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults

NCT05266456
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
24 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
835 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
13
States / cities
Hollywood, Florida • Sunrise, Florida • Savannah, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 7, 2026, 1:08 AM EDT